Author

L. Rong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Bioengineering· 1 Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 5 Organism:mouse· 4 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:protein structure· 2 Approach:deep learning· 1 Organism:non-human primate· 1

Frequent Co-Authors

L. Cooper· 4 shared A. B. Malik· 2 shared E. Procko· 2 shared J. Rehman· 2 shared K. K. Chan· 2 shared L. Zhang· 2 shared A. Aguhob· 1 shared A. Dwivedy· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

L. Cooper

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Optimal control of combination immunotherapy for a virtual murine cohort in a glioblastoma-immune dynamics model

H. G. Anderson, G. P. Takacs, J. K. Harrison, L. Rong, T. L. Stepien

This paper optimizes combination immunotherapy regimens for glioblastoma using a virtual murine cohort and finds personalized treatment improves survival.

bioRxiv · Apr 29, 2024Cancer Biology

Designer DNA NanoGripper

L. Zhou, Y. Xiong, L. Cooper, S. Shepherd, T. Song, A. Dwivedy, L. Rong, T. Wang, B. Cunningham, X. Wang

The paper designs, synthesizes, and characterizes a DNA nanorobot, NanoGripper, capable of capturing viral particles and functioning as a biosensor for SARS-CoV-2 detection in human saliva.

bioRxiv · Apr 26, 2023 · PreprintBioengineering

Avian and Human Influenza Viruses Exhibit Distinct Glycoconjugate Receptor Specificities in Human Lung Cells

C.-Y. Liang, I. Huang, J. Han, S. Manivasagam, J. Plung, M. Sturtz, Y. Yu, M. Kandasamy, F. A. Gourronc, A. J. Klingelhutz, B. Choudhury, L. Rong, J. T. Perez, S. Neelamegham, B. Manicassamy

The paper shows human and avian influenza viruses use different glycoconjugate types for infection, with avian strains using a broader range.

bioRxiv · Jun 29, 2022Microbiology

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2

L. Zhang, K. K. Narayanan, L. Cooper, K. K. Chan, C. A. Devlin, A. Aguhob, K. Shirley, L. Rong, J. Rehman, A. B. Malik, E. Procko

bioRxiv · Mar 28, 2022 · PreprintMicrobiology

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants

L. Zhang, S. Dutta, S. Xiong, M. Chan, K. K. Chan, T. M. Fan, K. L. Bailey, M. Lindeblad, L. M. Cooper, L. Rong, A. F. Gugliuzza, D. Shukla, E. Procko, J. Rehman, A. B. Malik

This study shows an engineered ACE2 peptide effectively mitigates ARDS and death in mice infected with multiple SARS-CoV-2 variants.

bioRxiv · Dec 21, 2021Pharmacology & Toxicology

Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures

Z. Shen, K. Ratia, L. Cooper, D. Kong, H. Lee, Y. Kwon, Y. Li, S. Alqarni, F. Huang, O. Dubrovskyi, L. Rong, G. R. Thatcher, R. XIONG

This study identifies potent non-covalent SARS-CoV-2 PLpro inhibitors that block viral replication in human and monkey cell cultures with low nanomolar potency.

bioRxiv · Feb 13, 2021Microbiology

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong, B. Beddingfield, J. Crabtree, R. A. Tripp, X. Qin, J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

bioRxiv · Jun 15, 2020 · PreprintImmunology